Category Archives: Genetic Engineering

image:The Journal encompasses study and debate on a broad range of environmental justice topics at the local, national, and global level. The Journal features studies that demonstrate the adverse effects that disparities in burden of hazards, environmental exposures, access to economic and ecologic resources, planning, and enforcement of regulations have on the health, safety, and welfare of communities of color, low-wealth populations, immigrants, indigenous peoples, and other groups fighting for environmental justice. view more

Credit: Mary Ann Liebert, Inc., publishers

The U.S. Department of Health and Human Services (HHS) announced that it is establishing an Office of Environmental Justice (OEJ) in response to President Bidens Executive Order Tackling the Climate Crisis at Home and Abroad.

[The] announcement is a key step toward confronting environmental injustice in all of its heartbreaking forms with the full force and commitment of the Federal government, White House Council on Environmental Quality Chair Brenda Mallory said in a statement.

This is a momentous occasion for folks that have been fighting for justice for the last 40 years to finally have the U.S. Department of Health and Human Services have an Office of Environmental Justiceit's not just the EPA anymore, Sacoby Wilson, PhD, director of the Center for Community Engagement, Environmental Justice, and Health, and professor with the University of Maryland-College Park, and Editor-in-Chief of the journal Environmental Justice, states. We need to make sure that health is at the forefront of all environmental and climate justice policies; with the new OEJ, there will be more resources, more research, and more input to address these conditions, he added.

The stated purpose of the Office of Environmental Justice is to undertake actions that seek to directly improve the wellbeing of underserved communities, including low-income communities and communities of color, who continue to bear the brunt of pollution from industrial development, agricultural practices, cumulative impacts of land use decisions, transportation and trade corridors.

About the Journal

Environmental Justice is an authoritative peer-reviewed journal published bimonthly online with Open Access and in print options. The Journal encompasses study and debate on a broad range of environmental justice topics at the local, national, and global level. The Journal features studies that demonstrate the adverse effects that disparities in burden of hazards, environmental exposures, access to economic and ecologic resources, planning, and enforcement of regulations have on the health, safety, and welfare of communities of color, low-wealth populations, immigrants, indigenous peoples, and other groups fighting for environmental justice. A complete table of contents and a sample issue may be viewed on the Environmental Justice website.

About the Publisher

Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science, medicine, biomedical research, and law. A complete list of the firms more than 100 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Environmental Justice

Observational study

People

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
'Not just the EPA anymore': New Office of Environmental Justice within U.S. Department of Health and Human Services - EurekAlert

Over the last century, the field of genetics and biotechnology has greatly developed because of the better understanding of the gene. Because of the improvement of technology, scientists have already gone up until the manipulation of the genome (complete set of genes) of organisms. This process is called genetic engineering. In this article, we will explore 13 important genetic engineering pros and cons.

The sharing of genetic material among living organisms is known to be a natural event. This phenomenon is known to be very evident among bacteria, hence they are called natures own genetic engineer. Such phenomenon is the inspiration of scientists in this endeavor.

In literature, there are in fact many synonyms of the term genetic engineering: genetic modification, genome manipulation, genetic enhancement, and many more. However, this term shall not be confused with cloning because genetic engineering involves the production of new set of genes while the latter only involves the production of the same copies of genes in the organism.

Genetic engineering is the process of manipulating an organisms genome using biotechnology and the products of it are either referred to as genetically modified or transgenic organisms. Check out the disadvantages of genetically modified foods here.

Basically, genetic engineering is done by inserting a gene of interest from sources like bacteria, viruses, plants, and animals into the target organism. As a result, the organism with the inserted gene of interest is now able to carry out the new trait or characteristic.

This technology grants us the ability to overcome barriers, exchange genes among organisms, and produce new organisms with favorable traits.

For a more detailed explanation of the process, check out this video below:

Now we will dive into the pros and cons of Genetic Engineering now.

Supporters of genetic engineering believe that genetic engineering is indeed safe and is still comparable to the traditional process of breeding in plants and animals. Advocates of genetic engineering support the technology primarily because of the following reasons:

On the other hand, there are several types of potential health effects that could arise from the insertion of a novel gene into an organism. Critics disagree with the methods of genetic engineering because of:

Because of the technology used to create genetically modified crops and animals, private companies that produce them do not share their products at a reasonable cost with the public.

In addition, they believe that the process is somewhat disrupting the natural way and complexity of life. In addition to this, critics fear the misuse and abuse of biotechnology.

Indeed, genetic engineering will always have two opposite sides. While the possibilities of what science can create are endless, and the harmful effects also are. At present, it is important to know that the real risks and benefits of genetic engineering lie in how science is interpreted and used.

But theres really no doubt that with the rapid advancements in technology, the creation of GM organisms are also increasing.

What do you think? Are GM organisms slowly becoming the future?

See original here:
13 Important Genetic Engineering Pros And Cons - Bio Explorer

Published 06-02-22

Submitted by Bayer

The carrot on your plate might seem like the most simple thing in the world a hardy root that has nourished humans, from kings to peasants, for generations. But as humble as it seems, the common carrot long, orange and crunchy is actually just one result of a genetic engineering project that has been going on for the last ten thousand years. In the wild, carrots are small, pale and have thin, forked roots with a strong flavor. Only centuries of selective breeding for desirable traits has given us the carrot we see today.

The fact is, a huge amount of the fruit and vegetables we take for granted never looked that way to begin with. These are the results of the great story of human agriculture, a story in which our prehistoric ancestors methodically identified plants with desirable traits the biggest, most flavorsome, or most disease resistant and cross bred them.

While individually, the changes can be minor, over time, that process has radically reshaped what we put on our plates. Consider the brassica this single plant, carefully cultivated over centuries has given us kale, broccoli, brussels sprouts, cauliflower, cabbage and turnips.

But as remarkable as all this is, the story is far from over.

Modern Problems...

Prehistoric agriculturists made the breeding decisions they did to cope with their environment. When food was scarce, making that ear of corn more nutritious and more weather resistant could be the difference between life and death over a long and cold winter. Of course, these farmers didnt have a scientific understanding of the genetics underlying this process. Crop improvement was slow and produced random results, as genes interacted in unpredictable ways at the molecular level. Civilization and science have come a long way since then, but we face our own set of challenges.

"The world population is growing, and climate zones are changing constantly; with this there is more pressure on plants from diseases, and insects. We need scientific answers to these problems."Jonathan Jenkinson, Head of Product Design at Bayer

Theres also the small matter of commercial imperatives. It doesn't take a crop scientist to point out that we like to buy things that taste better, look edible and stay fresh on the shelf for longer, whatever the season. Probably the biggest thing that has happened to impact what's on your plate is the ability to grow and ship fruits and vegetables year round, says Tom Osborn, Head of Vegetable Analytics and Pipeline Design at Bayer.

In response, agricultural scientists and plant breeders continue to innovate, creating crop varieties adapted to different growing conditions around the world that are more nutritious, more resistant to drought, disease and other forms of environmental stress as well as prettier and tastier.

Need Modern Solutions

But unlike farmers of the past, todays plant scientists have a vastly expanded set of tools available to them, which they are using to transform how we practice plant breeding to improve the food supply.

Every year, Bayer deploys over 500 new hybrids and varieties across corn, cotton soybeans and vegetables

Phenotyping

Traditionally, the process by which farmers have bred plants has been phenotyping. Phenotyping means assessing a plant's expressed traits and then selecting the desired plants and seeds. In practical terms this means visually identifying differences within plants for example, selecting for desirable colors, sizes, or number of fruits.

Plants reproduce by pollinating themselves or each other, so all the traditional agriculturist needed was to plant the seeds of the healthiest of their crop, and then they would grow, and fertilize each other, leading to a new generation of plants with the range of inherited traits contained in the parents. Though an imprecise science selective breeding could often produce random results as breeders had limited knowledge of the genetic mechanisms at work over time it led to significantly improved products. However, traditional plant breeding has seen significant changes over the last 15 years due to the introduction of genetic sequencing.

Genotyping

Now rather than just being able to see the results of breeding through phenotyping, we can see what happens to the structure of DNA and know why these changes occur in the plant at a genetic level this is called genotyping. And thanks to recent developments in genetic science (three decades of rapid improvement in genetic technologies in order to understand human genetics and health), mapping out the DNA of humans, animals, plants and all living organisms is quicker and cheaper than ever.

This means that scientists are now using technology to identify individual genes within plants, giving them a deep understanding of exactly what clusters of DNA are responsible for certain traits and characteristics. This gives scientists an unprecedented ability to develop seed varieties for specific environments and markets.

Want a strain of corn that is specifically resistant to your drought? Thanks to genotyping, a plant breeder could go in and identify which parts of the DNA strand can give resistance to that, and only breed seeds with those genetics. Breeders can then select those seeds, and distribute them as a standalone or product.

Gene Editing

Gene editing has the potential to solve real challenges for farmers and the planet, like reducing the need for pesticides and the use of energy, land, and water. In agriculture, this process typically looks to improve a beneficial trait within an organism, or to remove an undesirable trait. For years, gene editing was done through selective breeding in plants. But now we can make changes with more precision than ever before.

Gene editing tools, like CRISPR, are already helping researchers to make improvements within plant DNA. These tools have the potential to offer unmatched precision to farmers, allowing them to grow enough food while confidently reducing their use of natural resources. Its important to note, as well, that although plant breeding is a form of genetic engineering, it is not the same as genetic modification, or GM.

Data Analytics

And its not just about the seeds themselves. Coupled with broader technological improvements into data gathering and analysis, the process by which genes are selected and new crops make it into fields and onto your table is more efficient than ever before. If we can use data to make a better decision today about which corn hybrids to produce over the winter, that can get us to a new commercial product much faster, says Jonathan Jenkinson.

For him, who spent years working on-site in plant breeding programs, the result is significant. When I started researching in the field, I had to save all the seed from every plot and put it in a bag, and then take it back to the building where our facilities were. That meant moving about 30 tons of seed by hand, in the form of little bags that weighed three kilograms each. And that, of course, slowed the time-to-market right down.

Thanks to the development of modern data capture and analytics techniques, today its a very different story and thats good news for global farmers who are looking for solutions. In the last 30 years, it's probably gone from a time to market of 11 to 13 years, down to 6 or 7 years, says Jonathan.

As communities continue to fight poverty, hunger and malnutrition, its our responsibility to expand the reach and impact of Bayers global breeding resources. We approach this in a number of ways, but chief among them are the ways that we work outside of our walls to improve the seeds available to global farmers including partnerships aimed at knowledge-sharing, and germplasm and data contributions.

Why Collaboration is Key

Innovations in plant breeding have advanced the prosperity of civilizations for centuries. Continuously improving seeds to grow more resilient and high-yielding, more nutritious crops remains one of agricultures strongest tools in fighting hunger and supporting the farmers who feed communities around the world. Bayer develops crops using cutting edge breeding technologies and an expansive library of germplasm. And even with the resources of a market leader, the challenges facing agriculture cant be tackled by a single player alone. Having diverse germplasm living genetic resources such as seeds or plant tissues that are maintained for the purpose of plant breeding and preservation to tap into when developing new seed varieties makes plant breeders more successful in solving the problems facing global farmers and thats where collaboration comes in.

And thats why Bayer contributes germplasm and genetic characterization data to other research programs around the world. The donation is intended to facilitate the incorporation of underutilized genetic diversity into modern maize breeding programs including organizations that help improve regional crops for smallholders based on regional needs.

Donating germplasm isnt the only way that Bayer collaborates. Since 2020, Bayer has partnered with the International Institute of Tropical Agriculture to launch the Modern Breeding Project, focused on realizing crop resilience and yield potential for cassava, maize, cowpea, banana, yam, and soybean to support crop productivity, economic growth, and poverty reduction for African agriculture.

The project builds capacity and scale by leveraging insights from Bayers breeding program models and best practices. Our shared goals in leveraging research and product development are providing new solutions towards food security and empowering African scientists and farmers, supporting Africa rising to achieve the grand challenges in the face of climate change while developing new ways of working in a dynamic food system, says Stella Salvo, Head of Breeding Partnerships for Smallholder Farming at Bayer. Our Bayer breeding teams engage in sharing best practices in breeding program management, design and use of digital tools that will support the IITAs research priorities and product outputs.

The Breeding Story Continues

And thats not all. Crop scientists currently consider themselves to be moving from the third generation of breeding, powered by genomic knowhow, and into a fourth generation. The goal is to build more flavorful, sustainable, and high yielding crops, which are more resilient against climate change from the ground up. And scientists they will do this for example by harnessing the targeted abilities of gene editing techniques.

I would say the fourth era of breeding will be what were calling precision breeding at Bayer, says Jonathan. Weve become really good at knowing how to find the best traits; that's what we perfected over the last 30 years. But precision breeding seeks to fundamentally change that entire approach. Instead of selecting the best traits, we are moving to an era where can actually design what's going to be the best from the very beginning.

View original content here

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to http://www.bayer.com.

More from Bayer

Link:
Survival of the Best: The Past, Present and Future of Plants - CSRwire.com

"The year 2022 is still full of opportunities and challenges. We will continue to strengthen care technology based on the protein technology platform. Vazyme has been dedicated to our mission 'Science and Technology Make a Healthier Life'to focus on technology innovation and continuously expand the application fields of care technologies in life science, biomedicine, in vitro diagnostics, animal health and synthetic biology in human health. We have been holding ourselves to pursue the highest standards in quality of products and services for our customers and partners. Our global business network and operations make sure we could be close to the local markets, and more importantly, to do as much it can to meet the unmet customers' needs", said Cao Lin, chairman and founder of Vazyme.

This year also marks the Vazyme's 10th anniversary. Moving forward, the company plans to ramp up efforts in R&D and innovation, continuously upgrade and transform its core technologies, and expand business in new sectors. As one of the few R&D-focused biotech company in China, Vazyme holds a longstanding commitment in technology innovation. Over 2000 papers have been published by Vazyme in top academic journals worldwide, including more than 260 in CNS(stands for Cell, Nature, Science). By 2022, it has some 3000 employees and 27% of that are in the R&D team.

"Looking ahead, we will make further inroads in our key businesses and expand into new domains. I believe the market demand for COVID-19 and other related detection materials and products will continue to be strong. During the pandemic, China has remained one of the largest supplier for COVID-19 detection products."said Cao. In addition to pandemic-induced detection businesses, other regular detection products will be further developed, according to Cao. "When the prevention and control of the pandemic become regular, there will be new demands for detection products. In the future we will focus on the development of that,"added Cao.

Vazyme can not only provide COVID-19 and other related detection materials and products, but only offer various products and solutions in life-science industry for universities, laboratories, and related R&D centers, such as scientific research reagents, NGS Library Prep Kits and molecular diagnostics solutions. Currently, Vazyme has over 200 kinds of genetic engineering recombinases, more than 1,000 kinds of high-performance antigens, monoclonal antibodies, and other key raw materials, in addition to over 600 finished products.

As Vazyme's 10th anniversary slogan "Together for a Better Future", Vazyme aims to get close to its partners for a better future. In the future, Vazyme will provide better products and solutions, contribute to improve R&D efficiency for its partners, realize more scientific breakthroughs and dedicating to the mission "Science and Technology Make a Healthier Life".

Photo - https://mma.prnewswire.com/media/1830488/image_1.jpg

SOURCE Vazyme

Excerpt from:
Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future - PR Newswire

DUBLIN, June 2, 2022 /PRNewswire/ --The "Global Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Products, Technology, and Application" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

The global synthetic biology market is expected to grow from US$ 10,544.16 million in 2021 to US$ 37,850.85 million by 2028; it is estimated to grow at a CAGR of 20.0% from 2021 to 2028. The report highlights trends prevailing in the synthetic biology market and factors driving its growth. The increasing investments in synthetic biology and the rising number of start-ups are driving the market growth. However, the renewed regulations for biotechnology hamper the market growth.

Synthetic biology is the science of designing, altering, and building simple organisms to perform specific therapeutic or industrial utilities. The organisms created are genetically modified organisms (GMOs), which do not require a definition that distinguishes them from genetic modifications.

The rising number of start-ups is expected to support market growth during the forecast period. Biotechnology entrepreneurs easily raise funds and procure equipment and space from governments of the respective countries. Indie Bio (California, US) and EU (Ireland) are among the first synthetic biology accelerators. The start-ups are emerging in Asia Pacific, as governments in this region are providing funds for the domestic development of synthetic biology.

For instance, the Government of India funded IITM Bioincubator, a department of the Indian Institute of Technology Madras, to start a state-of-the-art research facility for cancer biology and a Bioinformatics Infrastructure Facility. The funds were provided by agencies such as the Council of Scientific and Industrial Research (CSIR), the Department of Biotechnology (DBT), and the Department of Science and Technology (DST).

The Indian Institute of Technology Madras raised US$ 7.86 million (550 million rupees) in the fiscal year 2016-2017. In China, Chinaccelerator is a financer that provides mentorship programs for helping start-ups. It is also associated with SOSV, a venture capital and investment management firm,, which helps establish start-ups by providing funds under programs such as RebelBio and Indie Bio. The easy availability of funds for ideas is motivating entrepreneurs in the world to establish synthetic biology businesses.

Story continues

Based on product, the synthetic biology market is segmented into oligonucleotides, chassis organisms, enzymes, and xeno-nucleic acid. The oligonucleotides segment is likely to hold the largest share of the market in 2021. Moreover, the same segment is anticipated to register the highest CAGR in the market during the forecast period of 2021 to 2028. Based on technology, the synthetic biology market is segmented into, gene synthesis, genome engineering, measurement & modeling, cloning & sequencing, nanotechnology, and others. In 2021, the gene synthesis segment is likely to hold the largest share of the market. However, the genome engineering segment is expected to register highest CAGR during 2021 to 2028. The growth of genome engineering segment is owing to the rising applications of genetic engineering and gene therapy.

Further, based on application, the synthetic biology market is segmented into medical applications, industrial applications, environmental applications, food and agriculture, and others. The medical applications segment is further segmented as, drug discovery & therapeutics and pharmaceuticals. In 2021, the medical applications segment held the largest market share, and it is expected to register the highest CAGR during 2021-2028.

Various organic and inorganic strategies are adopted by companies operating in the synthetic biology market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies have allowed the synthetic biology market players in expanding their business and enhancing their geographic presence, along with contributing to the overall market growth. Additionally, growth strategies such as acquisitions and partnerships helped them strengthen their customer base and extend their product portfolios.

Key Topics Covered:

1. Introduction

2. Key Takeaways

3. Research Methodology

4. Synthetic Biology Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America PEST Analysis4.2.2 Europe PEST Analysis4.2.3 Asia Pacific PEST Analysis4.2.4 Middle East & Africa PEST Analysis4.2.5 South & Central America PEST Analysis4.3 Experts Opinion

5. Synthetic Biology Market - Key Market Dynamics5.1 Market Drivers5.1.1 Increasing Investments in Synthetic Biology5.1.2 Rising Number of Start-Ups5.2 Key Market Restraints5.2.1 Renewed Regulations for Biotechnology5.3 Key Market Opportunities5.3.1 Collaboration Between Companies5.4 Future Trends5.4.1 Advanced Synthetic Biology5.5 Impact Analysis

6. Synthetic Biology Market - Global Analysis6.1 Global Synthetic Biology Market Revenue Forecast and Analysis6.1.1 Global Synthetic Biology Market Revenue Forecast and Analysis6.1.2 Global Synthetic Biology Market - Market Potential Analysis, By Region6.2 Company Analysis6.2.1 Market Positioning of Key Players6.2.2 Comparative Company Analysis6.2.3 Growth Strategy Analysis6.2.4 Performance of Key Players6.2.4.1 Thermo Fisher Scientific6.2.4.2 Twist Bioscience6.2.4.3 Agilent Technologies, Inc.

7. Synthetic Biology Market Analysis - By Product7.1 Overview7.2 Synthetic Biology Market, By Product, 2021 & 2028 (%)7.3 Enzymes7.3.1 Overview7.3.2 Enzyme: Synthetic Biology Market Revenue and Forecasts to 2028 (US$ Million)7.4 Oligonucleotides7.4.1 Overview7.4.2 Oligonucleotide: Synthetic Biology Market Revenue and Forecasts to 2028 (US$ Million)7.5 Chassis Organisms7.5.1 Overview7.5.2 Chassis Organisms: Synthetic Biology Market Revenue and Forecasts to 2028 (US$ Million)7.6 Xeno-Nucleic Acids7.6.1 Overview7.6.2 Xeno-Nucleic Acids: Synthetic Biology Market Revenue and Forecasts to 2028 (US$ Million)

8. Synthetic Biology Market Analysis - By Technology8.1 Overview8.2 Synthetic Biology Market Share by Technology - 2021 & 2028 (%)8.3 Gene Synthesis8.3.1 Overview8.3.2 Gene Synthesis: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)8.4 Genome Engineering8.4.1 Overview8.4.2 Genome Engineering: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)8.5 Measurement and Modeling8.5.1 Overview8.5.2 Measurement and Modeling: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)8.6 Cloning and Sequencing8.6.1 Overview8.6.2 Cloning and Sequencing: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)8.7 Nanotechnology8.7.1 Overview8.7.2 Nanotechnology: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)8.8 Others8.8.1 Overview8.8.2 Others: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)

9. Synthetic Biology Market Analysis - By Application9.1 Overview9.2 Synthetic Biology Market Share by Application - 2021 & 2028 (%)9.3 Medical Applications9.3.1 Overview9.3.2 Medical Applications: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.3.2.1 Drug Discovery and Therapeutics9.3.2.1.1 Overview9.3.2.1.2 Drug Discovery and Therapeutics: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.3.2.2 Pharmaceuticals9.3.2.2.1 Overview9.3.2.2.2 Pharmaceuticals: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.4 Industrial Applications9.4.1 Overview9.4.2 Industrial Applications: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.5 Food & Agriculture9.5.1 Overview9.5.2 Food & Agriculture: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.6 Environmental Applications9.6.1 Overview9.6.2 Environmental Applications: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)9.7 Others9.7.1 Overview9.7.2 Others: Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)

10. Global Synthetic Biology Market - Geographic Analysis

11. Impact Of COVID-19 Pandemic on Synthetic Biology Market11.1 North America: Impact Assessment of COVID-19 Pandemic11.2 Europe: Impact Assessment of COVID-19 Pandemic11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic11.5 South and Central America: Impact Assessment of COVID-19 Pandemic12. Synthetic Biology Market - Industry Landscape12.1 Overview12.2 Growth Strategies in the Synthetic Biology Market (%)12.3 Organic Developments12.3.1 Overview12.4 Inorganic Developments12.4.1 Overview

13. Company Profiles13.1 THERMO FISHER SCIENTIFIC INC.13.1.1 Key Facts13.1.2 Business Description13.1.3 Products13.1.4 Financial Overview13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Agilent Technologies, Inc.13.2.1 Key Facts13.2.2 Business Description13.2.3 Products and Services13.2.4 Financial Overview13.2.5 SWOT Analysis13.2.6 Key Developments13.3 MERCK KGaA13.3.1 Key Facts13.3.2 Business Description13.3.3 Products and Services13.3.4 Financial Overview13.3.5 SWOT Analysis13.3.6 Key Developments13.4 New England Biolabs13.4.1 Key Facts13.4.2 Business Description13.4.3 Products and Services13.4.4 Financial Overview13.4.5 SWOT Analysis13.4.6 Key Developments13.5 Integrated DNA Technologies13.5.1 Key Facts13.5.2 Business Description13.5.3 Products and Services13.5.4 Financial Overview13.5.5 SWOT Analysis13.5.6 Key Developments13.6 Twist Bioscience13.6.1 Key Facts13.6.2 Business Description13.6.3 Products and Services13.6.4 Financial Overview13.6.5 SWOT Analysis13.6.6 Key Developments13.7 GenScript Biotech Corporation13.7.1 Key Facts13.7.2 Business Description13.7.3 Products and Services13.7.4 Financial Overview13.7.5 SWOT Analysis13.7.6 Key Developments13.8 Novozymes A/S13.8.1 Key Facts13.8.2 Business Description13.8.3 Products and Services13.8.4 Financial Overview13.8.5 SWOT Analysis13.8.6 Key Developments13.9 Codexis13.9.1 Key Facts13.9.2 Business Description13.9.3 Products and Services13.9.4 Financial Overview13.9.5 SWOT Analysis13.9.6 Key Developments13.10 Amyris Inc.13.10.1 Key Facts13.10.2 Business Description13.10.3 Products and Services13.10.4 Financial Overview13.10.5 SWOT Analysis13.10.6 Key Developments

14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/otcjef

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/insights-on-the-synthetic-biology-global-market-to-2028---featuring-thermo-fisher-scientific-agilent-technologies-and-new-england-biolabs-among-others-301560327.html

SOURCE Research and Markets

See the rest here:
Insights on the Synthetic Biology Global Market to 2028 - Featuring Thermo Fisher Scientific, Agilent Technologies and New England Biolabs Among...

How Synthetic Biology Could Change Life as we Know it

Synthetic biology (synbio) is a field of science that redesigns organisms in an effort to enhance and support human life. According to one projection, this rapidly growing field of science is expected to reach $28.8 billion in global revenue by 2026.

Although it has the potential to transform many aspects of society, things could go horribly wrong if synbio is used for malicious or unethical reasons. This infographic explores the opportunities and potential risks that this budding field of science has to offer.

Weve covered the basics of synbio in previous work, but as a refresher, heres a quick explanation of what synbio is and how it works.

Synbio is an area of scientific research that involves editing and redesigning different biological components and systems in various organisms.

Its like genetic engineering but done at a more granular levelwhile genetic engineering transfers ready-made genetic material between organisms, synbio can build new genetic material from scratch.

This field of science has a plethora of real-world applications that could transform our everyday lives. A study by McKinsey found over 400 potential uses for synbio, which were broken down into four main categories:

If those potential uses become reality in the coming years, they could have a direct economic impact of up to $3.6 trillion per year by 2030-2040.

The medical and health sector is predicted to be significantly influenced by synbio, with an economic impact of up to $1.3 trillion each year by 2030-2040.

Synbio has a wide range of medical applications. For instance, it can be used to manipulate biological pathways in yeast to produce an anti-malaria treatment.

It could also enhance gene therapy. Using synbio techniques, the British biotech company Touchlight Genetics is working on a way to build synthetic DNA without the use of bacteria, which would be a game-changer for the field of gene therapy.

Synbio has the potential to make a big splash in the agricultural sector as wellup to $1.2 trillion per year by as early as 2030.

One example of this is synbios role in cellular agriculture, which is when meat is created from cells directly. The cost of creating lab-grown meat has decreased significantly in recent years, and because of this, various startups around the world are beginning to develop a variety of cell-based meat products.

Using synthetic biology, products could be tailored to suit an individuals unique needs. This would be useful in fields such as genetic ancestry testing, gene therapy, and age-related skin procedures.

By 2030-2040, synthetic biology could have an economic impact on consumer products and services to the tune of up to $800 billion per year.

Synbio could also be used to boost efficiency in clean energy and biofuel production. For instance, microalgae are currently being reprogrammed to produce clean energy in an economically feasible way.

This, along with other material and energy improvements through synbio methods, could have a direct economic impact of up to $300 billion each year.

While the potential economic and societal benefits of synthetic biology are vast, there are a number of risks to be aware of as well:

According to a group of scientists at the University of Edinburgh, communication between the public, synthetic biologists, and political decision-makers is crucial so that these societal and environmental risks can be mitigated.

Despite the risks involved, innovation in synbio is happening at a rapid pace.

By 2030, most people will have likely eaten, worn, or been treated by a product created by synthetic biology, according to synthetic biologist Christopher A. Voigt.

Our choices today will dictate the future of synbio, and how we navigate through this space will have a massive impact on our futurefor better, or for worse.

See more here:
Visualizing The 50 Biggest Data Breaches From 20042021 - Visual Capitalist

HONG KONG--(BUSINESS WIRE)--More than 25 percent of all marine species are supported by coral reefs. They provide for the lives and livelihoods of people throughout the world, yet their future is uncertain. Mary Kay, a global sustainability advocate, celebrates World Reef Day by supporting coral reef protection and restoration initiatives, including the Nature Conservancys Super Reefs project.

Coral reefs are magnificent structures with contributions to oceans that are unmatched. They not only provide food and habitats for many species, but they are living ramparts that actively protect our coastlines from waves and wave energy. Healthy reefs can reduce wave energy by up to 97%. Thus, they serve as living breakwaters, protecting tens of thousands of kilometers of coastline from seasonal flooding and erosion.

Despite their importance to our ecosystem, reefs are being degraded due to pollution, destructive fishing practices, and climate change. Rising ocean temperatures threaten their existence and make extinction a real possibility.

The window of opportunity to save the worlds coral reefs is closing, said Dr. Lizzie Mcleod, Global Reef Systems Lead at The Nature Conservancy. We must act now to save these vital habitats.

Hope is here. Super Reefs are resilient and can survive the warmer ocean waters because of their ability to adapt to higher temperatures. Some of these resilient reefs are also naturally located in areas protected from heat. Their potential to survive climate change gives hope for the future, especially in Asia Pacific where tropical waters are filled with at least 500 species of reef-building corals. The Nature Conservancys Super Reef team unites experts in ocean science and conservation to grow a global network of super reefs through genetic engineering, reef restoration, and coral farming.

Coral reefs can still be saved, but real action must take place to ensure their survival. The first step is to identify and protect Super Reefs. Once protected, they can breed strong larvae and create a new generation of resilient corals. With the continuing work and support of Mary Kay, coral reefs still have a chance.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our worlds toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit http://www.nature.org or follow @nature_press on Twitter.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching womens lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

Visit link:
Mary Kay Inc. Finds Hope Through Super Reefs in Mission to Save Our Oceans - Business Wire

We bet youre quite familiar with the phenomenon of robots taking over the world. And we surely wont be surprised to see that happening too soon, considering the fast-paced digital world that were all accustomed to.

As it is, artificial intelligence is ruling todays world, and as more and more research uncovers the great benefits of this ordeal, theres bound to be a lot of change taking place by 2025.

But the real question on our minds is how much is too much? Do we really want a world that replaces humans altogether? Are we ready to say hello to all things automated?

On one end of the spectrum, weve got no questions being asked in terms of artificial intelligence replicating the human mind and body in terms of labor. Yes, its a great development and we dont mind seeing automation taking command of some of the worlds most difficult and dangerous jobs.

Similarly, so many processes are getting simplified and that enhances a users experience in general. Be it data processing or even intricate execution, your algorithms are your strength and when a firm is nailing that aspect, there are no complaints.

As mentioned by one leading research by Tradeshift, machines are excelling at their game and in the end, theyll be the ones providing great solutions for mankind.

But with the positives come the negative and while technology can be great, programming a robot to perform a skill can be a daunting task. And you certainly cant expect any human to get the job done right because there is very little room to work with.

Imagine a world where humans train robots and robots perform tasks for the betterment of humans- what a unique world indeed.

The news comes as were being made aware of how Elon Musks Tesla failed to meet its yearly target for production. And thats when we saw the CEO come forward and admit that there was one robot too many in the firm, despite the fact that everything is super technical.

But Musk conveniently shifted the blame to robots in general, adding how everything was super automated in his company. Thankfully, the billionaire says its a mistake that he acknowledges and now his Tesla Model 3 is suffering. This was closely followed by another statement on Twitter where he revealed that humans were underrated and definitely deserved so much more credit than theyre given,

He also felt that is the edge that gives his organization an upper hand against other rivals in the market. But that again makes any sane person wonder how the underproduction of Tesla model 3 was due to robots, despite them being so efficient.

Look, we believe that no matter how hard and well you train your robots, theyll never be as efficient as humans and their hard and soft skills. After all, not everyone has the ability to implement the world of AI with great success.

Those that believed they could solely rely on AI in the past have failed with their project designs miserably and if thats not a wake-up call, then were not quite sure what is.

In general, we feel that if robots dont have humans in the workplace, they just might end up merging with them to establish a new form of a human in augmented shape.

Today, humans are being enhanced via plastic surgery to look a certain way or behave in a certain manner, thanks to the world of drugs that empower humans' skills and their performance in general.

Soon, were going to be seeing humans connecting their minds to different networks performing online. Were also going to be seeing genetic engineering take a new turn while bioprinting in 3D is another aspect worth the glance.

But how ethical is human enhancement? Are we okay with brain chips being implemented into our minds? Clearly, we dont think its normal because youre de-tracking the mind from doing something that they were planning to do.

Meanwhile, were also hearing science experts say we wont be having any decision-making power soon as everything will lie in the hands of robots. For now, we just hope AI is used for the betterment of society and not the exact opposite.

Theres nothing worse than knowing youve been fired because a robot was better than you, had more skills than you, or if the robot felt you just were not fit for the job.

We might be getting too far ahead of ourselves with this debate and for now, were just hoping Musk and others start to value humans before its too late.

More here:
Elon Musk Feels Humans Are Underrated As Tesla Criticized For Using Too Many Robots Instead Of 'Real People' - Digital Information World

Youve heard of fermenting yeast to make beer, but what about brewing GM microbes to make bioplastic? Using designer microbes to make stuff in fermentation vats has been described as the next manufacturing revolution, with potential to produce everything from cow-free cheese to sustainable fossil fuel replacements. But is GE-free New Zealand ready for it?

Veronica Stevenson bet her house deposit on a bee.

Before using GM microbes to make stuff was all the talk (Impossible Burger, mRNA vaccines), Stevenson set out to find the genetic recipe for the plastic-like film that lines the nest of a solitary Aussie bee.

All she had to do was work out which bit of the bees DNA linked to the nest material and put that code into a micro-organism, which then makes it in a fermentation vat, or bioreactor.

READ MORE:* The secret to the perfect dairy free cheese could lie in lab grown milk protein* Snail farming, cricket flour, algae and lab-grown fish; Welcome to the brave new world of alternative protein* Fermentation might lead to a dairy protein to make fake milk* US testing begins on genetically modified ryegrass developed in NZ

Finding the bees was a nightmare. Sequencing the genome was tricky. Gathering funding was challenging (hence investing her house deposit).

Still, she overcame every obstacle.

Weve sequenced the genome. Weve expressed the genome in two microbial systems. So weve proven that we can make it. Which is a massive thing.

But when it came to the trial and error stage of perfecting the process, Stevenson ran into the legacy of New Zealands famously strict genetic engineering rules, which the Productivity Commission this month concluded failed to take into account tech advances, and should be reviewed.

Because the regulatory environment is what it is, theres just no infrastructure, Stevenson says. Just the ability to move through the product from concept to commercial viability.

http://www.flickr.com/us

The Australian native bee, Hylaeus Nubilosis, which lines its nest hole with a natural bioplastic.

In December, Stevensons company Humble Bee announced a six-month partnership with United States biotech company Gingko Bioworks.

Their automated system can test 3000-5000 gene variants, different microbial hosts and processes to devise the perfect formulation. Its the genetic equivalent of a sophisticated recipe tester, trying out thousands of tweaks to ingredients, quantities, or temperatures.

While New Zealand may never be able to justify a research facility on Gingkos scale, Stevenson is frustrated the country is not doing more to embrace the multibillion-dollar potential of synthetic biology.

In Australia, three or four years ago, they realised this was huge ... and they threw hundreds of millions of dollars at it. They have a centre for research excellence on it. They have a venture capital fund specifically for this space.

And New Zealand is like, its just not on the radar. Which is a real shame. I just feel like were missing out.

LAWRENCE SMITH/Stuff

Nikki Freed and Irina Miller, co-founders of Daisy Lab, aim to create a milk protein in the lab.

While most Kiwis probably eat GM wheat, corn and soy in imported foods, the idea of releasing genetically engineered organisms is likely to remain a hard sell in New Zealand. Stevenson and many scientists argue we should at least have the conversation.

But the beauty of the technology behind Humble Bee is that the end product is not genetically modified.

Known as precision fermentation, the process is a hot topic because it can be used to make anything from fossil-free biofuels to the animal-free milk products that some predict will bring down the dairy industry.

Basically, you isolate the DNA sequence that encodes for something you want to make, insert it into a microbial host, which then produces it in a fermentation vat.

The product is then extracted and purified from the fermentation soup, or from the microbe itself.

The stuff were doing is not scary, says Stevenson. What were going to produce is not going to be released into the wild. Its not going to have an impact, interacting or sharing genes with other things. Its not going to cross-pollinate with something. Its an inert substance.

Its a big vat. You pull out whats expressed from the microbes and you give it to your biofabricators and they can make it into a film or turn it into a yarn. And then that gets incorporated into clothes. Its like synthetic spider silk.

It's not a new process its been used for 40 years to make insulin, as an alternative to extracting it from pig pancreases.

But the field is burgeoning now, because the comparative ease of genome sequencing and DNA synthesis means its suddenly accessible. Pfizer used it to make its Covid vaccines, and Impossible Foods ferments genetically engineered yeast to make the heme that gives its plant-based burger its meaty taste.

As Scions biotechnology research group leader Gareth Lloyd-Jones explains, 20-30 years ago you might get a PhD for cloning one gene.

Whereas now, you could probably in a month design an experiment to clone any gene, and order it, get somebody to synthesise the DNA for you, and deliver that in a form which you can put into the host, and the DNA vector you want to use to produce it.

All the technology around how you make it is cheaper. The amount of options as to what you can produce it in is broader. So everything has become so much bigger in terms of what you could think of doing.

So how is New Zealand placed to get its slice of the pie?

John Selkirk/Stuff

LanzaTech co-founder Sean Simpson says New Zealands restrictive GM regulations are technical masochism, preventing commercialisation of bright ideas.(File photo)

Remember LanzaTech, New Zealands biotech poster child, which in 2014 moved to the United States?

Founder Sean Simpson started out using a microbe that naturally converts carbon dioxide into ethanol in a process called gas fermentation. The idea was to capture carbon from industrial waste and transform it into a fossil fuel replacement a climate change double whammy.

But that was just the beginning. The real prize was to genetically engineer that microbe to make other things acetone or the starting materials for rubber or plastics.

But Simpson knew New Zealands regulations would prevent him doing that at scale. It wasnt the only factor that pushed him offshore, but it was a factor.

If we're going to use agricultural waste, societal waste, industrial waste to deliver sustainable fuels and chemicals, and replace oil, then biology has a significant part to play ... And New Zealand is basically saying, we don't want any part of that. Which is fascinating to me.

Contrary to popular belief, there is no ban on genetic modification here. You can apply under the Hazardous Substances and New Organisms Act (HSNO) to do genetic engineering, but it has to be done in containment. That means inside an approved and regularly audited facility.

That was never going to work for LanzaTechs industrial-scale bioreactors, and scientists say the approval process for GM development outside containment is so difficult it creates an effective moratorium. That closes off opportunities to turn great ideas into businesses, Simpson says.

Its not like we cannot undertake genetic manipulation in New Zealand. We can, and we do. We don't want to do it at a certain scale.

And I can't understand the justification for that. It's technical masochism. We're going to build a little bit of it, but when it gets really exciting, we're going to stop. If this could turn into something, we're not going to do it.

What Veronica has done is remarkable. But imagine the number of people who never even bothered to try and get that far, because of the hurdle that they knew was ahead of them.

Supplied

Kiwi Matt Gibson took his company making animal-free dairy mozzarella to San Francisco, after struggling to get it off the ground in New Zealand.

In Matt Gibsons profile pic, hes proudly sporting a vintage All Blacks jersey. But the New Culture founder is beaming in from San Francisco, where hes developing animal-free dairy mozzarella.

Dairy cheese has a terrible environmental footprint, making it a prime target for sustainability advocates, Gibson says. But the plant-based alternatives are pretty awful.

But what if you could cut out the middle gal the cow and make dairy cheese without the climate guilt?

Milk protein casein gives cheese its character the melt, the stretch, the flavour.

So thats what Gibson makes, using precision fermentation. He genetically engineers microbes to produce casein in fermentation tanks.

The extracted and purified casein is the same as casein from milk, and its not GM. The genetic manipulation occurs only in the process, not the product. Its then combined with plant-based fats and transformed into mozzarella through traditional cheesemaking.

Hes hoping to start selling commercially next year.

We are making animal-free dairy cheese today. Were making a lot of it. It melts, it stretches, it browns. It does everything youd expect dairy mozzarella to do.

But it wont be doing any of those things in New Zealand.

Supplied

New Cultures animal-free mozzarella melts, stretches and browns the same as the cow-made version.

Gibson started New Culture in Auckland in 2018.

He needed a lab for initial experimentation, but universities werent interested (he didnt want to sponsor a PhD student and lose control of the intellectual property). Commercial labs were keen to help, but their GM approvals were too narrow.

I just realised there was no way I could do any work, without having to get my own certification and set up my own lab, and that would cost a lot of money, compared to the United States, where nothing like that is required.

After six months of trying, I realised it was a fruitless endeavour.

So he moved to San Francisco, where he joined the IndieBio accelerator programme.

And now hes making cheese and New York Times headlines far from home.

Ultimately, if New Zealand doesnt embrace this, they are going to be left behind, and the future of dairy is going to be elsewhere, and it will be a shame.

Mike Scott/Stuff

Some predict animal-free dairy made using precision fermentation could spell the death of the dairy industry.

Reports of the dairy industrys imminent death have been greatly exaggerated.

Non-dairy products make up 15 per cent of the US dairy market, and a think tank report suggested animal-free dairy could kill off the cow milk industry by 2035.

That, says Gibson, is fantasy. His back-of-an-envelope calculation estimates just replacing New Zealands dairy output would require pretty much every existing fermentation tank in the world.

Its not going to happen in 10 years.

But its still a major risk for a country that relies so heavily on white gold, Gibson says.

The risk is that the economys biggest or second-biggest industry is going to become obsolete. Theres still going to be some demand for animal-derived dairy, but ultimately its going to become a niche product, and youre going to put a lot of people out of work.

Auckland Universitys 2020 Future of Food report notes international calls to swap from ruminant-based foods to plant-based ones could significantly affect the acceptability of New Zealands pastoral products in some markets.

The Ministry for Primary Industries, however, does not see novel methods for producing protein as a replacement for traditional forms. Any food produced with genetic modification also needs special Food Standards approval in New Zealand.

But the opportunities are much broader than just food. Australias Synthetic Biology Road Map estimates the technology of which precision fermentation is one part could be worth $27 billion a year and 44,000 jobs in Australia by 2040.

Whangarei Leader

Is precision fermentation the technology to win Kiwis over to GM?

But are GE-Free flag-waving Kiwi consumers ready to embrace genetic modification as a process rather than a product?

Humble Bees bioplastic is just one example of the technologys potential environmental wins providing more sustainable alternatives to fossil fuel-based products.

That means it has potential to win over the greenies who have traditionally opposed genetic modification.

Theres also a new generation of Kiwis who did not grow up in the shadow of GE-free placards. In 2019, 150 scientists aged under 30 signed an open letter to the Green Party asking them to reconsider their anti-GE stance.

Greenpeace does not oppose laboratory fermentation that does not result in environmental release of viable GM organisms. But they dont want to wait for lab-based food to reduce climate emissions.

Strong anti-GM voice The Sustainability Council would not say whether it opposes precision fermentation in principle, or its use to make casein, saying it has to assess every case separately. Executive director, Simon Terry, says using genetically modified organisms to aid fermentation is less risky for the environment than GM crops.

However, it should not be exempt from regulation, and the benefits should still have to outweigh the risks.

LAWRENCE SMITH/Stuff

It would be cheaper and easier to make animal-free dairy products almost anywhere else in the world, but Daisy Lab co-founder Nikki Freed is confident they can do it within New Zealands tough regulations.

One of the first questions potential investors ask about casein-culturing Kiwi startup Daisy Lab is Why would you be doing this in New Zealand? says co-founder Irina Miller.

Our response has always been well, yes, it is challenging. But its not impossible.

Both Miller and co-founder Nikki Freed are foreigners. They know it would be cheaper and easier to build their company just about anywhere else. But they want to do it here.

Im very interested in sustainability, says Freed, who is also the lead technologist at Auckland Universitys genomics facility. We want to see New Zealand succeed and become a great, green place for our kids to live.

Miller toyed with the idea of making animal-free dairy in 2016/17, while working for Fonterra. She figured someone else would do it. But when no-one did, she started Daisy Lab, in 2020.

LAWRENCE SMITH

Freed and Daisy Lab co-founder Irina Miller have been surprised at the lack of anti-GM feedback to their plans. (File photo)

The environmental gains from switching from cow udders to fermentation tanks could be huge, with one estimate finding it reduces greenhouse gas emissions by 91 to 97 per cent. There are no accurate estimates for New Zealands pasture-based farming.

Microbes still need to eat. Still researching at tiny scale, Daisy Lab is feeding its microbes pretty much pure sugar. But ultimately they hope to use food waste. If precision fermentation took off, farmers could grow sugar beets to feed the countrys army of micro-organisms.

Daisy Labs long-term vision is to tap into the dairy industrys supply chain for powdered milk, which is 80 per cent casein and makes up 95 per cent of all our milk exports. Farmers could be like micro-brewers, growing fermentation feed and making milk protein without the cow.

Freed and Miller have been surprised at the lack of backlash to their plans. Thats partly because people understand they wont actually be eating GMOs. But Freed thinks its also about their motivations.

At the heart of what were trying to do, is make a better planet. Were trying to improve sustainability. Were trying to improve animal welfare...Traditionally, other GMO have gotten a bad rap, because its more about making those seeds farmers have to buy each year. Its profit-driven.

Sarah Brook/Stuff

Synthase Biotech managing director Andy West says New Zealand could be making more high-value enzymes using precision fermentation. (File photo)

Read the original:
Is this the technology to win Kiwis over to genetic engineering? - Stuff

Albany NY, United States: CRISPR cas systems are commonly used in microbial engineering that includes immunization of cultures, bacterial strain typing, and self-targeted cell killing. Further, CRISPR and cas genes market system is also applied to control metabolic pathways for an improved biochemical synthesis. This technology is also used for the improvement of crop production. These factors further drive growth in the CRISPR and cas genes market.

CRISPR and cas genes system has been a revolutionary initiative in the biomedical research field. The application of this technology in somatic cell genome editing events has targeted to its application. The technologies are commonly used for the treatment of different genetic disorders. But, the ethical issues while using the system from the CRISPR and cas genes market are somewhere curtailing the growth in the industry. Furthermore, the market is also witnessing a lack of proficient professionals, which restrains its growth opportunities.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26417

The market forecast on CRISPR and cas genes market was estimated US$ 1,451.6 Mn. Now it is predicted to climb US$ 7,234.5 Mn during forecast period from 2018 to 2026. The market is estimated to reach a compound annual growth rate (CAGR) of 20.1% from 2018 to 2026.

Multiple Applications and Diverse Dominating Factors in CRISPR and Cas Genes Market

The report from market research on CRISPR and cas genes industry has marked its division on the basis of region, end-user, application, and product type. DNA-free cas and vector-based cas are the two types in which the CRISPR and cas genes market is bifurcated on the basis of product type. Between these two types, the vector-based cas section has dominated the market at international levelin 2017. This expression system is helpful for the researchers who are focusing to enrich Cas9-expressing cells and concentrate on the establishment of a stable cell line. The vector-based cas is available with an analytical that is used to support the creation of durable cell lines. These lines are designed with minimal possible background expression.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26417

The major advantages of the DNA-free cas segment boost growth in the CRISPR and cas genes market. DNA-free cas components are used for the reduction of potential off-targets. They also find application to trace correlations with human illnesses.

Knockout/activation, functional genomics, disease models, and genome engineering are the classification types in the CRISPR and cas genes market on the basis of application in different verticals. Contract research organizations, government and academic research institutes, pharmaceutical and biotechnology companies are some of the key end-use industries in the market. Further, as per the market analysis report on CRISPR and cas genes market, the industry is spread in different regions that include Middle East & Africa, Latin America, Asia Pacific, Europe, and North America.

Request for Analysis of COVID-19 Impact on CRISPR and Cas Genes Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=26417

The industry players from market have adopted inorganic and organic growth strategies for the expansion of product offerings, capturing market share, increasing consumer base, and strengthening geographical reach. Some of the key players in the CRISPR and Cas genes market include Dharmacon, Synthego, GenScript, OriGene Technologies, Inc., Applied StemCell, Inc., Addgene, and Cellecta, Inc.

Genome Engineering to Dominate CRISPR and Cas genes market

On the basis of application, the genome engineering section has dominated in the CRISPR and cas genes market. The genetic materials can be added, detached, and altered with the help of CRISPR technology at any specific location in the genome. Genomic engineering is related to the synthetic assembly of comprehensive chromosomal DNA, and it has been commonly taken from natural genomic sequences.

Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=26417

The CRISPR and Cas genes market has been dominated by pharmaceutical and biotechnology companies in terms of end-user. The strategic partnerships and innovations may boost growth in the market.

North America and Europe are the regions that account for the maximum share in the CRISPR and Cas genes market. Rising technological advancements and research activities are driving growth in the market.

Browse more Reports by Transparency Market Research:

High-flow Nasal Cannula Market: The global high-flow nasal cannula market is expected to be driven by the technological progress made by the prominent market players. In addition to that, clinical trials for the purpose of evaluation of new areas of application are likely to open up new avenues of growth for the global high-flow nasal cannula market in the years to come.

Blood Group Typing Market: The global blood group typing market is prophesied to gain impetus from the increasing number of applications in various types of tests. As noted by experienced analysts, antibody screening could draw a greater growth in the market due to the intensifying demand for the early diagnosis of diseases and swelling prevalence of chronic diseases.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Follow this link:
CRISPR and Cas Genes Market is Anticipated to Reach US$ 7,234.5 Mn by 2026, Increase in Incidence of Genetic Disorders to Drive the Market - BioSpace